Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 10/20 | 0.67 |
| ▸ | MMP2 | P08253 | 10/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28212986 | 1.00 | MMP9 (0.67) | MMP9MMP2ITGB3ITGA2BADAMTS4 | |
| SCHEMBL18720236 | 0.96 | MMP9 (0.61) | MMP9MMP2ITGB3ITGA2BADAMTS4 | |
| SCHEMBL200245 | 0.87 | MMP2 (0.57) | MMP9MMP2ITGB3ITGA2BMMP8 | |
| SCHEMBL200247 | 0.87 | MMP2 (0.57) | MMP9MMP2ITGB3ITGA2BMMP8 | |
| SCHEMBL29928063 | 0.86 | MMP9 (0.70) | MMP9MMP2ITGB3ITGA2BADAMTS4 | |
| SCHEMBL6562688 | 0.86 | MMP9 (0.87) | MMP9MMP2ITGB3ITGA2BADAMTS4 | |
| SCHEMBL6562692 | 0.86 | MMP9 (0.87) | MMP9MMP2ITGB3ITGA2BADAMTS4 | |
| Hydrochloric Acid SCHEMBL11406948 | 0.86 | MMP2 (0.56) | MMP9MMP2ITGB3ITGA2BMMP8 | |
| Hydrochloric Acid SCHEMBL920895 | 0.86 | MMP2 (0.56) | MMP9MMP2ITGB3ITGA2BMMP8 | |
| Hydrochloric Acid SCHEMBL15537019 | 0.85 | MMP2 (0.55) | MMP9MMP2ITGB3ITGA2BMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11197933-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200101166-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-04-02 | — | — | US | disclosed |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | MMP9 521/4885MMP2 538/4885ITGB3 2592/4885 |
| US-11197933-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRM1, OPRK1, OPRL1 | MMP9 1210/4885MMP2 874/4885ITGB3 1963/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | MMP9 521/4885MMP2 538/4885ITGB3 2592/4885 |
| US-20200101166-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRL1 | MMP9 1210/4885MMP2 874/4885ITGB3 1963/4885 |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | MMP9 521/4885MMP2 538/4885ITGB3 2592/4885 |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | MMP9 997/4885MMP2 1116/4885ITGB3 3041/4885 |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | MMP9 521/4885MMP2 538/4885ITGB3 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.